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EXECUTIVE SUMMARY
The Crohn’s and Colitis Foundation of America (CCFA) convenes meetings of leading
basic, translational and clinical researchers every four to five years to update progress on the
foundation’s research agenda and prioritize goals in inflammatory bowel diseases (IBD)
research. These multidisciplinary meetings are designed to identify cross cutting goals
across both basic and clinical research arenas. The goal of each meeting is to define the
overarching integrative global research mission and priorities of the CCFA for the ensuing
four-five years.
The first such meeting was in 1990, at which time a white paper entitled “Challenges in IBD
Research” was produced naming research priorities and resources necessary to reach these
goals. Updated “Challenges” documents have been produced at regular intervals since this
time. The most recent Challenges document was published in 2008.1 This document
described advances in basic and clinical research for the preceding interval years, and
identified major themes in research priorities to emphasize in the near future. During this
interval, advances were made in identification of genes, in understanding the association
between IBD and abnormal host responses to commensal bacterial flora, in the contribution
of the innate immune system to mucosal homeostasis, and elucidation of the cellular
populations and their mediators that drive and regulate immune responses. This document
identified important themes for research priorities from 2008-2012; including improved
tools for rapid identification of genes associated with IBD, enhanced tools for microbiome
analysis, genetic determined variances in responses to drugs and prognosis, and
improvement in therapeutic options for IBD management.
In June 2012, leading researchers representing committees composed of multidisciplinary
investigators drawn from a variety of research areas relevant to IBD pathogenesis and
treatment convened to review progress since the last document and identify new global
research priorities for the CCFA. The group concluded that since 2008, advances in basic
research have principally included:
• Significant and rapid progress has been made in identifying additional genetic loci
in Crohn’s disease (CD) and ulcerative colitis (UC), with over 160 published
susceptibility loci/genes to date.
• Fundamental insights into enteric microbiota community structure and genetic,
immunologic and microbial interactions have been made possible through rapid
advances in high-throughput DNA sequencing and bioinformatics technology.
These tools have allowed for identification of immunologic properties of individual
species and groups of bacteria and have provided evidence that host-associated
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bacterial communities are more complex in their interactions and biochemistry than
previously thought.
• The interaction of the intestinal microbiota and innate immune cells with the
mucosal adaptive immune system has been shown to play an important and
required role for the development of Th17 and regulatory T cells.
• There has been further discovery of novel functions and regulation for previously
recognized innate immune cells, as well as the discovery and characterization of
novel innate immune cell types such as innate lymphoid cells (ILCs).
Significant advances in clinical research have also occurred, with the following major
themes:
• Large cohort studies have been initiated to identify clinical or biological variables
that predict treatment outcome and risk stratification in pediatric IBD (e.g. RISK
Stratification Study and Predicting Response to Standardized Pediatric Colitis
Therapy “PROTECT”).
• Multicenter registries have been developed to determine the incidence of short- and
long-term adverse effects of medical therapies used to treat pediatric IBD.
• Prospective cohort studies have provided a better understanding of risks and
benefits of medical and surgical therapies in key sub-populations (e.g. Pregnancy in
IBD and Neonatal Outcomes study “PIANO”).
Based on these advances in the past 5 years, with further understanding of disease
pathogenesis and therapy, leading researchers developed a new research agenda for the
CCFA. This agenda is divided into 8 subgroups with a discrete research agenda for each
section. These sectional include epidemiology and environmental factors, IBD diagnoses,
optimizing medical therapy, genetics, microbiome, adaptive immunity, innate immunity, and
epithelial cell biology.
Genetics
Much progress has been made in the arena of IBD genetics over the past 5 years. Over 160
susceptibility loci/genes for CD and UC have been discovered to date. Included are genes
involved in IL23/Th17 signaling (IL23R, IL12B, JAK2, TYK2 and STAT3), as well as
IL10, IL1R2, REL, CARD9, NKX2.3, ICOSLG, PRDM1, SMAD3 and ORMDL3. For CD,
gene discoveries have focused upon the areas of defective processing of intracellular
bacteria, autophagy and innate immunity. 2-4 For UC, genetic evidence has demonstrated the
importance of barrier function.5 Emerging data also show an overlap of susceptibility loci
with other immune related diseases. However, data are lacking in very early onset IBD
(onset less than 10 years old), and non-European origin IBD cohorts. Therefore, further
research is needed in these specific groups. These genetic discoveries are a first step towards
an ultimate goal of personalized medicine in IBD.
Translation of these advances into the clinical sphere will include the use of genetic
information in diagnostics, predicting risk, individualizing therapy and development of
novel therapeutics that correct abnormal pathways. This will require the collection and
characterization of large, robustly phenotyped, prospective studies.
Genome-wide association (GWA) and linkage association studies have yielded important
insights and highlighted relevant pathways in the pathogenesis of CD and UC. However,
GWA approaches only identify regions that harbor risk genes, requiring follow-up studies to
discover the precise, disease-causing gene variants and their function. GWA studies describe
only a small fraction (about 25%) of inherited disease risk. Therefore, additional studies of
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epigenomics, gene-environment interactions, chromatin structure, copy number variants, and
microRNAs are needed in the coming years. It will be necessary to recruit well-
characterized, multiply affected family-based cohorts in order to explain both heritable traits
and identify rare but high effect variants. Further understanding of gene-microbial
interactions is also of utmost importance, particularly the role of host genomic variation in
determining microbial patterns.
Several approaches to bridging the bench to bedside divide have been proposed: making
genomics-based diagnostics routine; defining the genetic components of disease and
developing practical systems for clinical genomic informatics.6 It is also important to define
the functions of IBD risk alleles. These are areas where researchers should focus their efforts
in IBD.
Epidemiology and Environmental Factors
Over the past two decades, epidemiologic data have suggested that environmental factors
play a key role in the pathogenesis of IBD. However, conclusive evidence on the role of
specific environmental factors in either triggering or protecting against disease onset or
progression has been limited.
Methodological challenges within the field of IBD epidemiology have limited the ability to
draw firm conclusions from epidemiologic studies. These challenges include inconsistent
measurement (misclassification) of exposures and outcomes, the difficulty in recruiting and
following sufficient numbers of subjects for long enough time periods, and the inability
(until now) to measure and account for gene-environment interactions.
To account for the lack of large population-based cohort studies of IBD, an increasing
number of pharmacoepidemiologic studies have been performed. These studies, while
limited by factors such as lack of clinical data or incomplete capture of events, have led to
important advances in aspects of IBD management. We now have evidence of the long-term
effectiveness of biologic anti-tumor necrosis factor-alpha (anti-TNF) therapy in CD,7 the
relative and absolute risks of unintended outcomes including infection8, 9 and malignancy
(non-Hodgkin’s lymphoma,10 non-melanoma skin cancer,11, 12 and melanoma13) associated
with these and other medications, and preliminary evidence of the safety and effectiveness
of these agents in populations not initially studied in randomized trials.14, 15
With the above mentioned advances and limitations in mind, well designed epidemiologic
studies are needed in 3 major arenas. First, studies of disease etiology are needed, with a
particular focus on gene-environment interactions. These studies should incorporate the
simultaneous measurement of environmental and genetic factors prior to disease onset.
Second, studies of the natural history of disease are needed in order to evaluate the role of
environmental factors on flares/disease progression. Third, pharmacoepidemiological studies
of the absolute risks and benefits of available treatment options used under real-world
conditions and in diverse populations are needed to further inform treatment algorithms.
Microbiome
The enteric microbiota are now accepted as an important etiologic factor in the pathogenesis
of human IBD and immune mediated chronic experimental intestinal inflammation.16 Over
the past 5 years, there has been an explosive increase in understanding the fundamental
composition and community structure of the intestinal microbiota and how these enteric
bacterial species and their metabolic products interact with the host to mediate mucosal
homeostasis versus chronic intestinal inflammation. Insights into genetic, immunologic and
microbial interactions have flourished with identification of immunologic properties of
individual species and groups of bacteria.17, 18
Denson et al. Page 4













These dramatic advances have been made possible due to corresponding advances in
sequencing technology and the development of computational pipelines to handle these
larger datasets. These sequencing platforms permit a more comprehensive analysis of the
microbiota community structure, their genes and metabolic potential (through
metagenomics, metabolomics and metatranscriptomics) on a more affordable, relatively
rapid basis. Many of these advances were made possible through the CCFA Microbiome
Initiative and the National Institiute of Health’s (NIH) Human Microbiome Project.
Evidence suggests that host genes affect microbiota profiles and that specific commensal
microbes (either viruses or bacteria) selectively interact with host genes to influence
intestinal inflammation. Investigations using genetics/microbiome/ immunologic integration
hold great promise for the prospect of personalized medical care.
In order to further the understanding of microbiota in the pathogenesis of IBD, the
knowledge base must be expanded beyond broad descriptions of enteric bacterial taxonomy
to include individual bacterial species, functionally active strains, and other microbes,
including viruses, fungi and parasites. Of utmost importance is further comprehension of
how host genetics and environmental factors shape microbiota composition and function.
We also need to determine whether we can influence human disease outcomes in a durable
fashion by altering the composition and function of the gut microbiota using standard
therapeutic interventions, diet or fecal transplant. Ultimately, these findings may influence
clinical care via improved diagnosis, prediction of clinical course, treatment, prevention and
identification of clinically relevant disease subsets to achieve the hope of a personalized
medical approach for each individual with IBD.
Epithelial Cell Biology
The gastrointestinal epithelium and associated secreted products (mucus, antimicrobial
peptides, antibodies, etc.) serve as a selective permeable barrier that restricts access of
luminal antigens and viable microbes to underlying tissue compartments thereby playing a
pivotal role as a gatekeeper that controls overall mucosal homeostasis. Over the past 5 years,
advances in epithelial cell biology have included further understanding of mechanisms of
epithelial barrier compromise, the role of epithelia in controlling the intestinal immune
response and new insights into epithelial crosstalk with microbiota in IBD. CCFA funded
projects have demonstrated changes in intercellular junction proteins (occludin, claudins,
cadherins) that contribute to perturbed epithelial homeostasis and compromised barrier
function observed in IBD. It is now apparent that cytokines such as TNFα, IFNγ, IL-1β,
IL-13 have potent regulatory effects on expression and function of epithelial intercellular
junction proteins, polarity complexes and pattern recognition receptors that directly translate
to the barrier compromise observed in IBD patients. Lamina propria lymphocytes play an
important role in not only contributing to the mucosal barrier defense but also in directly
modulating epithelial differentiation and barrier function.
Gene linkage studies have provided new insights into epithelial dysfunction in CD.
Additionally, innate immune receptors such as Dectin-1 have now been linked to mucosal
responses to commensal fungal microorganisms that may play a role in pathobiology of
UC.19 The biology of other epithelial cell types, such as Paneth cells, and their roles in
intestinal host defense and homeostasis has been illuminated. Importantly, dysfunction of
Paneth cells is now thought to increase susceptibility to pathologic chronic intestinal
inflammation as seen in IBD.
Over the next 4-5 years, an emphasis upon understanding the mechanisms that influence
mucosal barrier function (and malfunction) is warranted. The outcome of such studies will
have important implications in defining IBD pathophysiology and potential therapeutic
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targets in IBD. In particular, it is important to understand what regulates intestinal epithelial
barrier function and how compromise of this function contributes to IBD pathogenesis.
Beyond understanding the barrier function, we need to determine how this function can then
be restored. Additionally, the interaction between the microbiota, epithelial homeostasis and
wound healing needs to be characterized. Further appreciation of the contributions of
inflammation and intrinsic epithelial growth regulatory signaling pathways to colitis-
associated carcinoma is also needed. Finally, the CCFA is interested in determining which
experimental models could contribute to the generation of basic cellular and molecular
understanding of intestinal epithelial cell biology.
Innate Immunity
Research in the field of innate immunity and mucosal immunology has been expanding
rapidly over the past 5 years, with the potential to dramatically impact future IBD
pathogenesis and management. Novel functions and regulation for previously recognized
innate immune cells have been discovered. Additionally, ongoing discovery and
characterization of novel innate immune cell types, such as innate lymphoid cells (ILCs),
has continued.20
Advances in other fields have contributed to these discoveries. For example, genetics and
microbiological analysis have affected the direction of innate immunity research. Functions
of genes have begun to be uncovered within specific innate immune cell types such as
monocyte-derived cells and Paneth cells. Our understanding of microbial-associated
molecular patterns (MAMPs, aka PAMPs) has significantly expanded our knowledge of
their related signaling pathways. In addition, the massive expansion of knowledge of the
intestinal microbiome has helped us identify potential microbes that normally interact with
and shape the innate immune system.
To this end, goals for the CCFA research agenda over the next five years include defining
new functional roles of known innate cell types, as well as elucidating the roles of emerging
innate immune cells. A deeper understanding of how IBD susceptibility polymorphisms and
IBD gene mutations affect innate immune function and intestinal immune homeostasis is
also needed. In particular, we need to clarify whether these mutations identify specific
pathways that can be explored experimentally and therapeutically. Finally, appreciating the
nature of the crosstalk of host innate immune cells with the microbiome is a fundamental
question and understanding these interactions will have a profound impact on IBD.
Adaptive Immunity
The adaptive immune system includes the antigen-specific immune responses mediated
primarily by T cells and B cells. While significant progress has been made in our
understanding of the role of the adaptive immune system in IBD pathogenesis, we have an
incomplete understanding of the pathways involved in the regulation of the adaptive
immune response to commensal bacteria and pathogens in the intestine. For example, the
role of Th17 effector cells in the pathogenesis of experimental IBD appears to be more
complicated than initially observed, with some studies suggesting a pathogenic role, while
others demonstrating a protective or regulatory role.21
Discoveries have also been made in understanding the relationship of the intestinal
microbiota and innate immune cells with the mucosal adaptive immune system. This
relationship has been reported to play an important and required role for the development of
Th17 cells.22-24 Specific microbes, or phyla of microbes, that are important for activating
Th17 immune responses have also been defined.25 It has also been suggested that
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stimulation of Th17 is required for the beneficial, as well as the pathogenic, effects of gut
immune responses.
Although significant progress has been made within the last five years in identifying
potential mechanisms involving the adaptive immune system in the pathogenesis of IBD,
more work is needed. In particular, knowledge gained thus far needs to be translated into
clinically relevant applications and appropriate tools (i.e., novel animal models) to address
emerging questions.
The CCFA is interested in supporting further efforts to define the precise phenotypic and
functional properties of T-effector and Treg/emerging regulatory subsets that distinguish
different forms of IBD. In addition, concepts generated from experimental models of IBD
need to be translated to the clinical setting. This can be accomplished via identification of
potential biomarkers for active disease or characterization of novel cytokines/mediators
involved in IBD pathogenesis that may be future therapeutic targets. To accomplish these
goals, there is an urgent need for development of humanized mouse models.
IBD Diagnoses: Clinical Classification and Prognostic Models
We have learned that both CD and UC patients have heterogenous genetic profiles.
Therefore, using genetic data in combination with other factors (clinical criteria, immune
profiles, intestinal gene expression patterns, and microbiome community structure) may
serve as an important prognostic tool to determine factors such as drug toxicity or response
to therapy. An important step in furthering this understanding is ongoing; the development
and follow-up of the prospective pediatric RISK cohort. This study examines the
relationship between genetic, serologic, immunologic and microbiologic factors and clinical
course of CD. Enrollment of the cohort was completed in 2011, and prospective three year
follow-up is ongoing. This cohort is an important step towards developing a tool, or series of
tools, to define prognosis in pediatric IBD.
Important advances have also been made in improving classification of IBD. A series of
three meetings took place in 2009 in order to define a new Paris classification system for
pediatric-onset IBD.26 This system can be used in conjunction with the existing Montreal
classification system. The two main additions include a definition of very early onset IBD as
< age 10 at onset, and early onset IBD as < age 17 at onset. In addition, modifiers for
extensive small bowel CD, growth failure, and severe UC were defined. A consensus
definition for “early” CD was also derived and validated over the past two years.27 The
primary features include duration of disease of not more than 2 years, no significant GI
dysfunction or fibrotic or penetrating complications, and no exposure to immune modulators
or biologics. This definition could be used to define a more homogenous patient population
for clinical trials of new disease-modifying therapies.
Little progress has been made in defining risks of rare adverse events of medical therapy.
Emerging cases of serious complications, such as hepatosplenic T-cell lymphoma28 and
progressive multifocal leukoencephalopathy29 have emphasized the importance of
understanding the individualized risks of therapies. Ongoing cohort studies will seek to
better define these long-term risks.
To further the advances made over the past 5 years, the most important research questions in
the arena of IBD diagnostics focus upon developing better ways to classify patients for
prediction of natural history, response to therapy, and adverse effects of therapy. Large
prospective cohort studies are needed to validate factors that predict those at risk for severe
disease or complications, and conversely, those patients with predicted mild courses. We
also need to understand the accuracy of diagnostic imaging modalities in monitoring
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inflammation and/or fibrosis, and to determine whether these studies can predict clinical
outcomes. Cost-effectiveness studies comparing strategies for disease management and
monitoring should be performed, along with implementation of tools for shared decision
making with patients.
Optimizing Medical Therapy
Progress has been made over the past 5 years in improving outcomes in children and adults
with IBD. In particular, strides have been made towards identifying variables that predict
treatment outcomes and allow for risk stratification of children with IBD. Currently, the
CCFA sponsored RISK Stratification Study is ongoing, which will also provide important
information on therapeutic outcomes. The PROTECT study will examine the relationship
between similar genetic, serologic, immunologic and microbiologic factors and the
likelihood of children newly diagnosed with UC maintaining remission on standard does of
mesalamine. The results of this study may allow for avoidance of unnecessary medications
(and ensuing side-effects) in a subgroup of patients. Other registry studies have also been
initiated to identify the incidence of adverse effects in IBD. In particular, we now have a
better understanding of the risks and benefits of medical and surgical therapies in population
subgroups; such as pregnant women with IBD.15
The research priorities for the CCFA in optimizing medical therapy in adults include a focus
upon individualized therapy. For example, individualization of anti-TNF therapy in IBD
may improve outcomes. A better understanding of the role of customized dosing frequencies
and adjustments in anti-TNF therapy and concomitant immunosuppressants is warranted.
Better prediction models for monitoring disease course and activity are needed. Along these
lines, objective instruments to validate CD activity in clinical trials are also considered
necessary. Importantly, a better understanding of when therapies can be reduced, or
“stepped-down,” during a lifetime of disease is warranted; as well as determination of
optimal therapies in specific subpopulations, such as the elderly.
Specific challenges in the management of pediatric IBD are also a focus for the CCFA. Of
particular importance is the ideal method of using anti-TNF therapy in pediatric CD
populations, including the role for and risks of combination therapy in patient subgroups.
Additionally, data are needed as to the best method to monitor success of therapies in the
pediatric population. For UC, an important emphasis over the next 5 years will be the
development of new strategies for the treatment of fulminant UC.
Summary of Global Priorities
The participants in the 2012 Challenges meeting identified the following integrative global
priorities for the CCFA’s research agenda:
• Define clinically relevant subsets of IBD patients using genetic, immunologic,
microbial, tissue expression, and clinical profiles (including drug metabolism and
pharmacokinetics) that will predict aggressiveness of disease, complications and
response to treatment.
• Understand how environmental factors enhance the risk of IBD through effects on
microbial, epigenetic, immunologic, and mucosal barrier influences.
○ A specific focus upon the role of diet is warranted.
• Determine which environmental triggers initiate, perpetuate, and/or reactivate
disease.
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• Further understand reciprocal interactions (cross-talk) between genes, microbiota,
epithelial cells, and innate and adaptive immune responses that determine pathways
mediating mucosal homeostasis versus inflammation.
○ Determine critical rate-limiting cell/cellular pathways for communication
with the microbiota.
○ Definition of critical cell types and the functional pathways leading to
further understanding of homeostasis versus inflammation, with an ultimate
goal of identifying putative (therapeutic) targets.
• Determine optimal treatment approaches and strategies through comparative
effectiveness studies.
To carry out this research agenda, the following resources are needed:
• Centralized and distrubutable infrastructure for biobanking, data warehouse, and
tissue/cell/ microbila repositories for integrated human investigation.
• Prospective cohort studies of pediatric and adult IBD patients with serial
biospecimens collected throughout the course of their diseases.
• Infrastructure to recruit and follow patients from childhood to adult life.
• Access to data and biospecimens collected prior to and following treatment with
established and novel therapeutics.
• Improved tools for measuring disease activity in IBD.
• More specific in vivo tools including humanized mice and lineage specific models
for mechanistic research.
• Availability of new methodology for improved cell lines and freshly isolated and
viable mucosal cells.
• Implementation of a series of workshops to improve IBD research methodology
and promote integrative multidisciplinary approaches and resources.
Since 1990, there has been remarkable progress in our understanding of the pathogenesis
and therapeutic targets in IBD, but further strides are needed. The CCFA has played a
central role in advancing this research. Through development of the ambitious research
goals outlined in this document, the CCFA has again led the effort to further the
understanding of IBD. The CCFA is keen to advance this research agenda in 2012 and
beyond.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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